Cabergoline, Pramipexole and Ropinirole Used as Monotherapy in Early Parkinsons Disease: An Evidence-Based Comparison

ISSN： 1170-229X

Source： Drugs & Aging, Vol.20, Iss.11, 2003-01, pp. : 847-855

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of the Risk of Adverse Events with Pramipexole and Ropinirole in Patients with Parkinsons Disease: A Meta-Analysis

By Etminan M.

Drug Safety, Vol. 26, Iss. 6, 2003-01 ,pp. : 439-444

Adis International

Access to resources Recommend Favorite

Ropinirole in the treatment of Parkinson’s disease

By Zesiewicz T.A. Hauser R.A.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 697-710

Informa Healthcare

Access to resources Recommend Favorite

Subcutaneous Apomorphine: An Evidence-Based Review of its Use in Parkinsons Disease

By Dirk Deleu

Drugs & Aging, Vol. 21, Iss. 11, 2004-01 ,pp. : 687-709

Adis International

Access to resources Recommend Favorite

A review of pramipexole and its clinical utility in Parkinson’s disease

By Holloway Robert G Biglan Kevin M

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 2, 2002-02 ,pp. : 197-210

Informa Healthcare

Access to resources Recommend Favorite

The Long-Acting Dopamine Receptor Agonist Cabergoline in Early Parkinsons Disease: Final Results of a 5-Year, Double-Blind, Levodopa-Controlled Study

By Fulvio Bracco

CNS Drugs, Vol. 18, Iss. 11, 2004-01 ,pp. : 733-746

Adis International

Access to resources Recommend Favorite